IP Library › Granted Patent US 12,404,324
Granted Patent B2
US 12,404,324 · App. 17/385,284 · Granted Sep 2, 2025

Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody

Inventors: Elizabeth Hsia (Kennett Square, PA); Xie Xu (San Marcos, CA)
Assignee: Janssen Biotech, Inc.
C07K16/244A61K9/0019A61K47/183A61K47/26A61K47/6849A61P19/02G16H50/30A61K2039/505C07K2317/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,324
App. No.
17/385,284
Granted
Sep 2, 2025
Kind
B2
Abstract

A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, PASI70/90/100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI/dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

Claims (49)

1. A method of treating psoriatic arthritis in a patient in need thereof, wherein the patient showed an inadequate response to or intolerance to standard non-biologic therapies for psoriatic arthritis, the method comprising:

(i) subcutaneously administering an antibody to IL-23 to the patient at a dose of 100 mg at week 0, a dose of 100 mg at week 4, and a dose of 100 mg every 8 weeks thereafter (q8 w),

wherein the antibody comprises a light chain variable region and a heavy chain variable region, said light chain variable region comprising: a LCDR1, a LCDR2 and a LCDR3 comprising the amino acid sequences of SEQ ID NO:50, 56 and 73, respectively; and said heavy chain variable region comprising: a HCDR1, a HCDR2 and a HCDR3 comprising the amino acid sequences of SEQ ID NO:5, 20 and 44, respectively; and wherein the antibody is in a composition comprising 100 mg/mL of the antibody, 7.9% (w/v) sucrose, 4.0 mM Histidine, 6.9 mM L-Histidine monohydrochloride monohydrate, and 0.053% (w/v) Polysorbate 80;

(ii) measuring whether the patient has achieved a statistically significant improvement in disease activity as determined by at least one endpoint of disease improvement selected from the group consisting of: the American College of Rheumatology 20% improvement criteria (ACR20), the American College of Rheumatology 50% improvement criteria (ACR50), the Psoriasis Area and Severity Index 75, 90 and 100 (PASI75/90/100), the American College of Rheumatology 50% and 70% improvement criteria (ACR50/70), Health Assessment Questionnaire Disability Index (HAQ-DI), Leeds enthesitis index (LEI), a dactylitis assessment score (0=absent, 1=mild, 2=moderate, 3=severe), Short Form Health survey (SF-36), mental and physical component summary (MCS and PCS), a minimal disease activity (MDA) criteria score, a Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) Index, modified Composite Psoriatic Disease Activity Index (mCPDAI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and the Routine Assessment of Patient Index Data 3 (RAPID3); and

(iii) determining that the patient is a responder to treatment with the antibody based on the result of the measurement in step (ii).

2. The method of claim 1 , wherein ACR20 is measured at week 16 of treatment with the antibody.

3. The method of claim 1 , wherein ACR20 is measured at week 24 of treatment with the antibody.

4. The method of claim 1 , wherein PASI75/90/100 is measured at week 24 of treatment with the antibody.

5. The method of claim 1 , wherein ACR50/70 is measured at week 24 of treatment with the antibody.

6. The method of claim 1 , wherein HAQ-DI is measured at week 24 of treatment with the antibody.

7. The method of claim 1 , wherein LEI is measured at week 24 of treatment with the antibody.

8. The method of claim 1 , wherein the dactylitis assessment score of 0-3 is measured at week 24 of treatment with the antibody.

9. The method of claim 1 , wherein SF-36 is measured at week 24 of treatment with the antibody.

10. The method of claim 1 , wherein MCS and PCS are measured at week 24 of treatment with the antibody.

11. The method of claim 1 , wherein MDA is measured at week 24 of treatment with the antibody.

12. The method of claim 1 , wherein PASDAS is measured at week 24 of treatment with the antibody.

13. The method of claim 1 , wherein GRACE Index is measured at week 24 of treatment with the antibody.

14. The method of claim 1 , wherein mCPDAI is measured at week 24 of treatment with the antibody.

15. The method of claim 1 , wherein DAPSA is measured at week 24 of treatment with the antibody.

16. The method of claim 1 , wherein RAPID3 is measured at week 24 of treatment with the antibody.

17. The method of claim 1 , wherein ACR20, ACR50, ACR70, PASI70, PASI90, PSAI100, MDA, HAQ-DI, LEI/dactylitis, SF-36 PCS, PASDAS, GRACE, mCPDAI, DAPSA, RAPID3 or MCS is measured 16, 20, 24 or 28 weeks after the initial treatment with the antibody.

18. The method of claim 1 , wherein the antibody is effective to reduce a symptom of psoriatic arthritis, induce clinical response, induce or maintain clinical remission, inhibit disease progression, or inhibit a disease complication.

19. The method of claim 1 , further comprising administering to the patient one or more additional drugs used to treat psoriasis arthritis.

20. The method of claim 19 , wherein the one or more additional drugs is selected from the group consisting of: an immunosuppressive agent, a non-steroidal anti-inflammatory drug (NSAID), methotrexate (MTX), an anti-B-cell surface marker antibody, an anti-CD20 antibody, rituximab, a TNF-inhibitor, and a corticosteroid.

21. A method of treating psoriatic arthritis in a patient in need thereof, wherein the patient showed an inadequate response to or intolerance to standard non-biologic therapies for psoriatic arthritis, the method comprising:

(i) subcutaneously administering an antibody to IL-23 to the patient at a dose of 100 mg at week 0, a dose of 100 mg at week 4 and a dose of 100 mg every 8 weeks thereafter (q8 w),

wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 106; and wherein the antibody is in a composition comprising 100 mg/mL of the antibody, 7.9% (w/v) sucrose, 4.0 mM Histidine, 6.9 mM L-Histidine monohydrochloride monohydrate, and 0.053% (w/v) Polysorbate 80;

(ii) measuring whether the patient achieves a statistically significant improvement in disease activity as determined by at least one endpoint of disease improvement selected from the group consisting of: the American College of Rheumatology 20% improvement criteria (ACR20), the American College of Rheumatology 50% improvement criteria (ACR50), the Psoriasis Area and Severity Index 75, 90 and 100 (PASI75/90/100), the American College of Rheumatology 50% and 70% improvement criteria (ACR50/70), Health Assessment Questionnaire Disability Index (HAQ-DI), Leeds enthesitis index (LEI), a dactylitis assessment score (0=absent, 1=mild, 2=moderate, 3=severe), Short Form Health survey (SF-36), mental and physical component summary (MCS and PCS), a minimal disease activity (MDA) criteria score, a Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) Index, modified Composite Psoriatic Disease Activity Index (mCPDAI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and the Routine Assessment of Patient Index Data 3 (RAPID3); and

(iii) determining that the patient is a responder to treatment with the antibody based on the result of the measurement in step (ii).

22. The method of claim 21 , wherein ACR20 is measured at week 16 of treatment with the antibody.

23. The method of claim 21 , wherein ACR20 is measured at week 24 of treatment with the antibody.

24. The method of claim 21 , wherein PASI75/90/100 is measured at week 24 of treatment with the antibody.

25. The method of claim 21 , wherein ACR50/70 is measured at week 24 of treatment with the antibody.

26. The method of claim 21 , wherein HAQ-DI is measured at week 24 of treatment with the antibody.

27. The method of claim 21 , wherein LEI is measured at week 24 of treatment with the antibody.

28. The method of claim 21 , wherein the dactylitis assessment score of 0-3 is measured at week 24 of treatment with the antibody.

29. The method of claim 21 , wherein SF-36 is measured at week 24 of treatment with the antibody.

30. The method of claim 21 , wherein MCS and PCS are measured at week 24 of treatment with the antibody.

31. The method of claim 21 , wherein MDA is measured at week 24 of treatment with the antibody.

32. The method of claim 21 , wherein PASDAS is measured at week 24 of treatment with the antibody.

33. The method of claim 21 , wherein GRACE Index is measured at week 24 of treatment with the antibody.

34. The method of claim 21 , wherein mCPDAI is measured at week 24 of treatment with the antibody.

35. The method of claim 21 , wherein DAPSA is measured at week 24 of treatment with the antibody.

36. The method of claim 21 , wherein RAPID3 is measured at week 24 of treatment with the antibody.

37. The method of claim 21 , wherein ACR20, ACR50, ACR70, PASI70, PASI90, PSAI100, MDA, HAQ-DI, LEI/dactylitis, SF-36 PCS, PASDAS, GRACE, mCPDAI, DAPSA, RAPID3 or MCS is measured 16, 20, 24 or 28 weeks after the initial treatment with the antibody.

38. The method of claim 21 , wherein the antibody is effective to reduce a symptom of psoriatic arthritis, induce clinical response, induce or maintain clinical remission, inhibit disease progression, or inhibit a disease complication.

39. The method of claim 21 , further comprising administering to the patient one or more additional drugs used to treat psoriasis arthritis.

40. The method of claim 39 , wherein the one or more additional drugs is selected from the group consisting of: an immunosuppressive agent, a non-steroidal anti-inflammatory drug (NSAID), methotrexate (MTX), an anti-B-cell surface marker antibody, an anti-CD20 antibody, rituximab, a TNF-inhibitor, and a corticosteroid.

41. The method of claim 21 , wherein the antibody is guselkumab.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2022
From: HSIA, ELIZABETH; XU, XIE
To: JANSSEN BIOTECH, INC.
Reel/Frame 061905/0607 →
Continuity (4)
Continuation 16181733 · Nov 6, 2018
Provisional Application 62744386 · Oct 11, 2018
Provisional Application 62581996 · Nov 6, 2017
Related Publication 20210363235A1 · Nov 25, 2021
References Cited (51)
US 20110206680A1 · Valdes · 2011 [cited by applicant]
US 20150147337A1 · Reichert · 2015 [cited by applicant]
US 20180094052A1 · Randazzo · 2018 [cited by applicant]
WO 2014004436 · 2014 [cited by applicant]
WO 2015119841 · 2015 [cited by applicant]
WO 2017172771 · 2017 [cited by applicant]
WO 2017180821 · 2017 [cited by applicant]
WO 2018093841 · 2018 [cited by applicant]
Clinical Trial NCT02319759 (v1, Dec. 18, 2014). [cited by examiner]
Ungprasert et al. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti… [cited by examiner]
Baeten, Dominique et al., “Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis,” The New England Journal of Medicine, vol. 373, issue 26 (Dec. 24, 2015) pp. 2534-2548. [cited by applicant]
Blauvelt, Andrew et al., “Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from … [cited by applicant]
Bowes, John et al., “Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis,” Annals of Rheumatological Diseases, vol. 70 (Apr. 24, 2011) pp. 1641-1644. [cited by applicant]
Brown, Alan , “Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series,” Open Access Rheumatology: Research and Reviews, vol. 2016, issue 8 (Nov. 11, 2016) pp. 97-102. [cited by applicant]
Coates, L.C., et al., “Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment,” Annals of Rheumatological Diseases, vol. 69 (Jan. 11, 2009) pp. 48-53. [cited by applicant]
Coates, Laura C. et al., “Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Tre… [cited by applicant]
Coates, Laura C. et al., “Validation of Minimal Disease Activity Criteria for Psoriatic Arthritis Using Interventional Trial Data,” Arthritis Care & Research, vol. 62, issue 7 (Jul. 7, 2010) pp. 965-969. [cited by applicant]
Deodhar, Atul et al., “Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomized, double-blind, placebo-controlled study,” Arthritis and Rheumatic Di… [cited by applicant]
Duerr, Richard D. et al., “A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene,” Science, vol. 314, issue 5804 (Dec. 1, 2016) pp. 1461-1463. [cited by applicant]
Feagan, B. G. et al., “Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease,” The New England Journal of Medicine, vol. 375 (Nov. 17, 2016) pp. 1946-1960. [cited by applicant]
Feagan, Brian G. et al., “Induction therapy with the selective interleukin-23 inhibitor Risankizumab in patients with moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled phase 2 study,” La… [cited by applicant]
Gordon, K. B. et al., “Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis,” The New England Journal of Medicine, vol. 375, issue 4 (Jun. 8, 2016) pp. 345-356. [cited by applicant]
Helliwell, Philip S. et al. “Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response,” The … [cited by applicant]
Helliwell, Philip S. et al. “Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity,” Arthritis Care & Research, vol. 70, No. 5 (Ma… [cited by applicant]
Helliwell, Philip S. et al., “Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data from an Interventional Study with Golimumab,” Arthritis Care & Research, vol. 66, No. 5 (May 2014) pp.… [cited by applicant]
Her, Minyoung et al. “A review of disease activity measures for psoriatic arthritis: what is the best approach?” Expert Review of Clinical Immunology, vol. 10, No. 9, (Aug. 4, 2014) pp. 1241-1254. [cited by applicant]
Huber, Wolfgang et al., “Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial,” Gut, vol. 61, issue 12 (… [cited by applicant]
Krstic, Aleksandra et al., “The potential of interleukin-17 to mediate hematopoietic response,” Immunology Research, vol. 52 (Mar. 4, 2012) pp. 34-41. [cited by applicant]
Langley, Richard G. et al., “Secukinumab in Plaque Psoriasis—Results of Two Phase 3 Trials,” The New England Journal of Medicine, vol. 371, issue 4 (Jul. 24, 2014) pp. 326-338. [cited by applicant]
Lebwohl, M. et al., “Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis,” The New England Journal of Medicine, vol. 373, issue 14 (Oct. 1, 2015) pp. 1318-1328. [cited by applicant]
Leonardi, Craig L. et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoen… [cited by applicant]
Liu, Ying, et al. “A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci,” PLoS Genetics, vol. 4, issue 3 (May 2008) e1000041 pp. 1-14. [cited by applicant]
Lloyd, Peter et al., “Psoriatic arthritis: an update,” Arthritis, vol. 2012 (Oct. 13, 2012) pp. 1-6. [cited by applicant]
Mease, P., “A short history of biological therapy for psoriatic arthritis,” Clinical and Experimental Rheumatology, vol. 33, suppl. 93 (Sep. 25, 2015) pp. S104-S108. [cited by applicant]
Medical Phamplet for TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval: 2016 (Revised May 2020). [cited by applicant]
Mumtaz, Aizad et al. “Development of a preliminary composite disease activity in psoriatic arthritis,” Annals of Rheumatological Disease, vol. 70, issue 2 (Apr. 1, 2011) pp. 272-277. [cited by applicant]
Nair, Rajan P. et al., “Genome-wide Scan Reveals Association of Psoriasis with IL-23 and NF-kappaB pathways,” Nature Genetics, vol. 41, issue 2 (Sep. 16, 2009) pp. 199-204. [cited by applicant]
NCT02319759 on Jan. 26, 2015; “A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis,” … [cited by applicant]
Olivieri, Ignazio et al., “Advances in the management of psoriatic arthritis,” Nature Reviews Rheumatology, vol. 10 , issue 9 (Jul. 8, 2014) pp. 531-542. [cited by applicant]
Orchard, T. R. et al., “Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history,” Gut, vol. 42, issue 3 (Mar. 1998) pp. 387-391. [cited by applicant]
Papp, Kim A. et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2),… [cited by applicant]
Rahman, Proton et al., “Association of Interleukin-23 Receptor Variants with Ankylosing Spondylitis,” Arthritis & Rheumatism, vol. 58, issue 4 (Apr. 2008) pp. 1020-1025. [cited by applicant]
Reich, Kristian et al., “Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal… [cited by applicant]
Sands, Bruce E, et al., “Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients with Moderate to Severe Crohn's Disease: A Phase 2a Study,” Gastroenterology, vol. 153, No. 1 (2017) pp. 77-86. [cited by applicant]
Scher, Jose U. et al., “Decreased Bacterial Diversity Characterizes an Altered Gut Microbiota in Psoriatic Arthritis and Resembles Dysbiosis of Inflammatory Bowel Disease,” Arthritis & Rheumatology, vol. 67, issue 1 (Ja… [cited by applicant]
Schoels, Monika M. et al., “Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score,” Annals of Rheumatological Diseases, vol. 75, issue 5 (Aug. 12, 2015) pp. 811-81… [cited by applicant]
Targan, Stephan R. et al., “A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn's Disease,” American Journal of Gastroenterology, vol. 111, issue 11 (Nov.… [cited by applicant]
Taylor, William et al., “Classification Criteria for Psoriatic Arthritis,” Arthritis & Rheumatism, vol. 54, issue 8 (Aug. 2006) pp. 2665-2673. [cited by applicant]
Nakamura et al., “Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials,” Dermatology and Therapy (2017), vol. 7, pp. 281-292. [cited by applicant]
Gossec, L. et al., “European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update,” Annals of Rheumatological Diseases (2016), vol. 75, … [cited by applicant]
Coates, L.C. et al., “ Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis ,” Arthritis & Rheumatology (2016), vol. 68, No. 5, pp. 1060-1071. [cited by applicant]